Witnessing the stock’s movement on the chart, on Wednesday, Spyre Therapeutics Inc (NASDAQ: SYRE) set off with pace as it heaved 10.36% to $17.68, before settling in for the price of $16.02 at the close. Taking a more long-term approach, SYRE posted a 52-week range of $10.91-$40.26.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 44.65%. Meanwhile, its Annual Earning per share during the time was 44.65%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 11.48%. This publicly-traded company’s shares outstanding now amounts to $60.74 million, simultaneously with a float of $51.03 million. The organization now has a market capitalization sitting at $1.07 billion. At the time of writing, stock’s 50-day Moving Average stood at $16.31, while the 200-day Moving Average is $17.48.
Spyre Therapeutics Inc (SYRE) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Spyre Therapeutics Inc’s current insider ownership accounts for 15.51%, in contrast to 99.46% institutional ownership. According to the most recent insider trade that took place on Sep 02 ’25, this organization’s Chief Financial Officer sold 18,428 shares at the rate of 16.26, making the entire transaction reach 299,639 in total value, affecting insider ownership by 97,994. Preceding that transaction, on Nov 06 ’24, Company’s Director sold 6,700 for 36.76, making the whole transaction’s value amount to 246,313. This particular insider is now the holder of 27,360 in total.
Spyre Therapeutics Inc (SYRE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
Spyre Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 11.48% and is forecasted to reach -3.24 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -2.52% through the next 5 years, which can be compared against the 44.65% growth it accomplished over the previous five years trading on the market.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Let’s observe the current performance indicators for Spyre Therapeutics Inc (SYRE). It’s Quick Ratio in the last reported quarter now stands at 6.49.
In the same vein, SYRE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.05, a figure that is expected to reach -0.76 in the next quarter, and analysts are predicting that it will be -3.24 at the market close of one year from today.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Going through the that latest performance of [Spyre Therapeutics Inc, SYRE]. Its last 5-days volume of 0.59 million was inferior to the volume of 0.61 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 63.82% While, its Average True Range was 63.83.
Raw Stochastic average of Spyre Therapeutics Inc (SYRE) in the period of the previous 100 days is set at 71.16%, which indicates a major fall in contrast to 93.52% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.00 that was higher than 0.95 volatility it exhibited in the past 100-days period.
